WallStSmart
NGNE

Neurogene Inc

NASDAQ: NGNE · HEALTHCARE · BIOTECHNOLOGY

$26.48
-3.53% today

Updated 2026-04-29

Market cap
$422.41M
P/E ratio
P/S ratio
438.73x
EPS (TTM)
$-4.24
Dividend yield
52W range
$12 – $37
Volume
0.2M

Neurogene Inc (NGNE) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201120122013201420152016201720182019202020212022202320242025
Revenue$25.00M$0.00$0.00$0.00$925000.00$0.00
Revenue growth (YoY)-100.0%-100.0%
Cost of revenue$125597.00$130784.00$59571.00$135946.00$340000.00$1.82M$42.26M$3.20M$3.26M$3.25M$3.19M
Gross profit$-125597.00$-130784.00$-59571.00$-135946.00$25.00M$-340000.00$-1.82M$-42.26M$-3.20M$-3.26M$-2.32M$-3.19M
Gross margin100.0%-251.0%
R&D$8.58M$5.91M$7.54M$17.94M$15.80M$28.38M$36.27M$32.79M$6.32M$24.34M$42.26M$47.51M$44.39M$60.92M$75.01M
SG&A$8.27M$9.01M$11.19M$22.61M$28.32M
Operating income$-10.43M$-7.68M$-9.38M$-22.38M$-21.34M$-37.65M$-51.12M$-23.52M$-24.44M$-41.55M$-50.53M$-56.52M$-55.58M$-82.61M$-103.21M
Operating margin-94.1%-8930.3%
EBITDA$-10.54M$-7.54M$-8.63M$-21.65M$-21.76M$-37.00M$-50.18M$-31.58M$-69.10M$-31.46M$-49.59M$-51.99M$-52.29M$-71.89M$-103.33M
EBITDA margin-126.3%-7771.4%
EBIT$-10.66M$-7.67M$-8.69M$-21.78M$-21.34M$-37.00M$-50.18M$-69.44M$-33.28M$-50.53M$-55.19M$-55.58M$-75.13M
Interest expense$42923.00$2.25M$99000.00$1000.00$4000.00$4000.00$1000.00$0.00$2000.00$12000.00$12000.00$5000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-10.51M$-7.71M$-8.73M$-23.82M$-21.86M$-37.00M$-50.18M$-31.59M$-69.44M$-33.28M$-50.52M$-55.19M$-36.32M$-75.14M$-90.35M
Net income growth (YoY)+26.6%-13.2%-172.9%+8.2%-69.3%-35.6%+37.1%-119.9%+52.1%-51.8%-9.2%+34.2%-106.9%-20.2%
Profit margin-126.3%-8123.7%